Largest Ever Real-World Evidence Study of Ambulatory Cardiac Monitoring Demonstrates Clinical Superiority of iRhythm’s Zio Long-Term Continuous Monitoring Service
SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) — (NASDAQ:IRTC) today announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal (AHJ).
Related news for (IRTC)
- iRhythm Technologies Announces First Quarter 2025 Financial Results
- iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
- iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
- irhythm technologies announces third quarter 2024 financial results
- irhythm technologies enters license agreement with biointellisense for multiparameter sensor technology to be used in ambulatory cardiac monitoring